Case Reports in Hematology最新文献

筛选
英文 中文
Management of Immune-Mediated Thrombotic Thrombocytopenic Purpura Without Plasma Exchange in a Jehovah's Witness: A Case Report. ​
IF 0.7
Case Reports in Hematology Pub Date : 2026-11-09 eCollection Date: 2026-01-01 DOI: 10.1155/crh/2753797
Carina Wong, Rakesh Mehta
{"title":"Management of Immune-Mediated Thrombotic Thrombocytopenic Purpura Without Plasma Exchange in a Jehovah's Witness: A Case Report.","authors":"Carina Wong, Rakesh Mehta","doi":"10.1155/crh/2753797","DOIUrl":"10.1155/crh/2753797","url":null,"abstract":"<p><p>Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic microangiopathy caused by severe ADAMTS13 deficiency and is traditionally treated with urgent therapeutic plasma exchange. Management becomes particularly challenging in patients who decline blood products. We report the case of a previously healthy woman with severe iTTP, with a platelet nadir of 6 × 10<sup>9</sup>/L, ADAMTS13 activity < 5%, and an ADAMTS13 inhibitor titer of 2 Bethesda units, who declined plasma exchange because of her religious beliefs as a member of Jehovah's Witnesses. She was treated with high-dose corticosteroids, rituximab, and adjunctive intravenous immunoglobulin (IVIG). Platelet count normalized by hospital Day 9 with progressive resolution of hemolysis, and at 6-month follow-up the patient remained in durable clinical and biochemical remission with normalization of ADAMTS13 activity. This case highlights the potential adjunctive role of IVIG within an immune-directed treatment strategy for iTTP when plasma exchange is not feasible.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"2753797"},"PeriodicalIF":0.7,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune Thrombotic Thrombocytopenic Purpura Presenting With Transient Neurological Deficits: A Case Report. 免疫性血栓性血小板减少性紫癜伴暂时性神经功能缺损1例报告。
IF 0.7
Case Reports in Hematology Pub Date : 2026-11-09 eCollection Date: 2026-01-01 DOI: 10.1155/crh/4650998
Hisham Eltayeb Ahmed Elhasan, Tarig Merghani, Fathelrahman Ahmed, Syed Majid Hamid, Azza Alawad
{"title":"Immune Thrombotic Thrombocytopenic Purpura Presenting With Transient Neurological Deficits: A Case Report.","authors":"Hisham Eltayeb Ahmed Elhasan, Tarig Merghani, Fathelrahman Ahmed, Syed Majid Hamid, Azza Alawad","doi":"10.1155/crh/4650998","DOIUrl":"10.1155/crh/4650998","url":null,"abstract":"<p><strong>Background: </strong>Immune thrombotic thrombocytopenic purpura (iTTP) is a rare but fatal disorder characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic damage of organs due to widespread platelet-rich thrombi in small blood vessels. Early detection and prompt treatment are crucial to reducing mortality.</p><p><strong>Case presentation: </strong>We report a case of a female, 66-year-old, who presented with transient episode of left-sided weakness and aphasia that resolved within 30 min. Initial neuroimaging showed no evidence of ischemia. Laboratory evaluation showed severe thrombocytopenia, severe anemia, high lactate dehydrogenase (LDH), reticulocytosis, and the presence of schistocytes in peripheral blood. The calculated PLASMIC score was 6, and ADAMTS13 activity showed severe deficiency, supporting the diagnosis of iTTP. The patient responded well to corticosteroids and therapeutic plasma exchange, with significant clinical and hematological improvement following the treatment. She was discharged after 2 weeks in good condition with a plan for regular follow-up.</p><p><strong>Conclusion: </strong>This case emphasizes the significance of including iTTP in the differential diagnosis of transient neurological attacks in patients with hematological abnormalities. Early initiation of plasma exchange and immunosuppressive therapy are essential to prevent organ damage and further complications.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"4650998"},"PeriodicalIF":0.7,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pirtobrutinib for the Treatment of Therapy-Resistant Chronic Lymphatic Leukemia With CNS Localization. 匹托鲁替尼治疗伴有中枢神经系统定位的耐药慢性淋巴白血病。
IF 0.7
Case Reports in Hematology Pub Date : 2026-10-20 eCollection Date: 2026-01-01 DOI: 10.1155/crh/1249723
M E Roerink, A P Kater, S H Tonino, E van der Spek
{"title":"Pirtobrutinib for the Treatment of Therapy-Resistant Chronic Lymphatic Leukemia With CNS Localization.","authors":"M E Roerink, A P Kater, S H Tonino, E van der Spek","doi":"10.1155/crh/1249723","DOIUrl":"https://doi.org/10.1155/crh/1249723","url":null,"abstract":"<p><p>During the last decade, many new treatment options for chronic lymphatic leukemia (CLL) have become available, one of them being covalent-binding Bruton's tyrosine kinase inhibitors (cBTK inhibitors [cBTKis]). There are currently three cBTKis approved for treatment of CLL/SLL: acalabrutinib, ibrutinib, and zanubrutinib. In relapsed and heavily pretreated patients, BTK inhibitors achieve a median PFS of 4 years, and in frontline, around 80% of CLL patients are still in remission and alive after 4 years of treatment with BTK inhibitors. Despite their efficacy, 40% of patients have to discontinue BTK inhibitors because of side effects or treatment resistance. We present the efficacy of the novel noncovalent BTKi in a patient with CLL who developed covalent BTKi-resistant disease with CNS localization. Pirtobrutinib appears to be effective in patients with ibrutinib resistance, even with CNS localization. Clinical responses may take several months to become evident.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"1249723"},"PeriodicalIF":0.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13681179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149239905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pacritinib-Based Salvage Therapy in High-Risk Polycythaemia Vera With Recurrent Arterial and Venous Thrombosis After Hydroxyurea and Ruxolitinib: A Case Report. 以帕西替尼为基础的挽救性治疗羟脲和鲁索利替尼后复发性动脉和静脉血栓形成的高风险真性红细胞增多症1例报告。
IF 0.7
Case Reports in Hematology Pub Date : 2026-10-16 eCollection Date: 2026-01-01 DOI: 10.1155/crh/8282682
Muna Al-Rasheed
{"title":"Pacritinib-Based Salvage Therapy in High-Risk Polycythaemia Vera With Recurrent Arterial and Venous Thrombosis After Hydroxyurea and Ruxolitinib: A Case Report.","authors":"Muna Al-Rasheed","doi":"10.1155/crh/8282682","DOIUrl":"10.1155/crh/8282682","url":null,"abstract":"<p><strong>Objectives: </strong>Polycythaemia vera (PV) is associated with substantial arterial and venous thrombotic risk, particularly in patients with prior thrombosis and inadequate haematocrit (HCT) control. Although ruxolitinib is an established second-line treatment after hydroxyurea failure or intolerance, some patients remain difficult to manage. We report a case of highly thrombotic, treatment-challenging PV in which pacritinib-based salvage therapy was used after inadequate disease control with hydroxyurea and ruxolitinib.</p><p><strong>Case presentation: </strong>A 44-year-old man was referred with portal vein thrombosis and a history of premature myocardial infarction and cerebrovascular accident. Investigations demonstrated JAK2V617F-positive PV with borderline low erythropoietin and bone marrow panmyelosis. Despite antiplatelet therapy, anticoagulation, hydroxyurea and subsequent ruxolitinib, the patient experienced further thrombotic complications, including recurrent cerebrovascular events, bilateral limb ischaemia and left ventricular thrombosis. Ruxolitinib was escalated to 25 mg twice daily and combined with low-dose hydroxyurea; however, HCT control remained suboptimal, with recurrent need for venesection. In February 2025, ruxolitinib was replaced with pacritinib 200 mg twice daily while hydroxyurea and warfarin were continued. During follow-up, the patient achieved improved HCT control, no longer required venesection and had no further documented thrombotic events. Pacritinib was well tolerated.</p><p><strong>Conclusion: </strong>This case describes a patient with high-risk, refractory PV and recurrent arterial and venous thrombosis in whom pacritinib-based salvage therapy was associated with improved HCT control, cessation of venesection and absence of further thrombosis during follow-up. Although off-label and hypothesis-generating, this experience supports further evaluation of pacritinib in selected patients with treatment-challenging PV.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"8282682"},"PeriodicalIF":0.7,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13673302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149217105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polycythemia Vera Transforming to Pure Erythroid Leukemia: A Diagnostic Mimic of Thrombotic Microangiopathy With High-Risk TP53 Biology. 真性红细胞增多症转化为纯红系白血病:具有高风险TP53生物学的血栓性微血管病的诊断模拟物
IF 0.7
Case Reports in Hematology Pub Date : 2026-10-15 eCollection Date: 2026-01-01 DOI: 10.1155/crh/8549290
Thalia Padilla Kelley, Lam Duc, Jean Sabile, Ronan Swords
{"title":"Polycythemia Vera Transforming to Pure Erythroid Leukemia: A Diagnostic Mimic of Thrombotic Microangiopathy With High-Risk TP53 Biology.","authors":"Thalia Padilla Kelley, Lam Duc, Jean Sabile, Ronan Swords","doi":"10.1155/crh/8549290","DOIUrl":"10.1155/crh/8549290","url":null,"abstract":"<p><p>Leukemic transformation of polycythemia vera (PV) to acute myeloid leukemia (AML) with a predominantly erythroid blast population is rare and carries a poor prognosis, particularly when driven by a TP53 mutation. We report a 55-year-old man with JAK2 V617F-positive PV, previously noted on surveillance biopsy to harbor a TP53 mutation and Grade 2 marrow fibrosis, who presented three years later with pancytopenia, schistocytosis, hyperferritinemia, hypofibrinogenemia, and altered mental status. The initial clinical presentation raised concern for thrombotic thrombocytopenic purpura (TTP), while the presence of rare circulating blasts and coagulopathy also prompted consideration of acute promyelocytic leukemia (APML). Empiric plasma exchange, corticosteroids, and all-trans retinoic acid were initiated. ADAMTS13 activity and PML-RARA FISH subsequently returned negative. The patient deteriorated with multiorgan failure and expired before leukemia-directed therapy could be initiated. Postmortem bone marrow results demonstrated greater than 90% erythroid blasts with TP53 protein overexpression, a TP53 p.C238Y mutation (VAF 66%), and a triploid karyotype with 7p and 19p abnormalities, consistent with pure erythroid leukemia (PEL) arising from an antecedent myeloproliferative neoplasm. This case highlights the diagnostic challenges posed by overlapping clinical features of TTP and APML, including limitations in immunophenotypic assignment of the erythroid lineage. Importantly, it provides a longitudinally documented example of a TP53 mutation detected three years before overt transformation and describes a previously unreported presentation mimicking both TTP and APML.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"8549290"},"PeriodicalIF":0.7,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13673119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149217062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Excellent Response to Eculizumab in a Patient With Complement-Mediated Thrombotic Microangiopathy and a Novel Plasminogen Gene Variant. 在补体介导的血栓性微血管病和一种新的纤溶酶原基因变异患者中,Eculizumab对其有极好的疗效。
IF 0.7
Case Reports in Hematology Pub Date : 2026-10-12 eCollection Date: 2026-01-01 DOI: 10.1155/crh/1318626
Aman Patel, Bowen Powers, Jason Tsai, Suresh Nukala
{"title":"Excellent Response to Eculizumab in a Patient With Complement-Mediated Thrombotic Microangiopathy and a Novel Plasminogen Gene Variant.","authors":"Aman Patel, Bowen Powers, Jason Tsai, Suresh Nukala","doi":"10.1155/crh/1318626","DOIUrl":"https://doi.org/10.1155/crh/1318626","url":null,"abstract":"<p><p>A middle-aged man presented with myalgia, fever, hematemesis, and melena. He was found to have acute kidney injury, acute coronary syndrome, thrombocytopenia, and Coombs-negative hemolytic anemia, raising concern for thrombotic microangiopathy (TMA). While awaiting confirmatory testing, empirical plasma exchange was initiated. Initially, minimal red blood cell fragmentation was observed, which later progressed to florid fragmentation. Despite supportive care, his clinical status deteriorated requiring hemodialysis. The presence of TMA, along with <i>ADAMTS13</i> metalloprotease activity above the diagnostic threshold, worsening kidney function, and negative stool Shiga toxin testing suggested complement-mediated TMA (C-TMA). Stool PCR testing revealed rotavirus. Eculizumab was initiated, resulting in rapid normalization of hematological parameters and eventual renal recovery. Genetic testing identified a heterozygous <i>PLG</i> c.1735G > A (p.Gly579Arg) variant classified as a variant of uncertain significance (VUS). The importance of serial review of peripheral blood smears and the diagnostic challenge of differentiating TTP, STEC-HUS, and C-TMA are the key learning points.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"1318626"},"PeriodicalIF":0.7,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149185229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypical Extramedullary Acute Myeloid Leukemia in Infancy: Bilateral Testicular Swelling and Scalp Lesions at Diagnosis. 婴儿期非典型髓外急性髓性白血病:诊断时双侧睾丸肿胀和头皮病变。
IF 0.7
Case Reports in Hematology Pub Date : 2026-10-12 eCollection Date: 2026-01-01 DOI: 10.1155/crh/2024335
Ruba Alhazaimeh, Mais Jazazi, Ayman Alhwayan, Sulieman Jaafreh, Hazem Haddad, Adnan Bwaneh, Tasneem Malahmeh, Maher Khader
{"title":"Atypical Extramedullary Acute Myeloid Leukemia in Infancy: Bilateral Testicular Swelling and Scalp Lesions at Diagnosis.","authors":"Ruba Alhazaimeh, Mais Jazazi, Ayman Alhwayan, Sulieman Jaafreh, Hazem Haddad, Adnan Bwaneh, Tasneem Malahmeh, Maher Khader","doi":"10.1155/crh/2024335","DOIUrl":"https://doi.org/10.1155/crh/2024335","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is rare in infancy, with monocytic subtypes such as acute myelomonocytic leukemia often demonstrating extramedullary involvement. This report describes a 10-month-old male infant presenting with firm bilateral testicular enlargement and multiple parietal scalp nodules, accompanied by leukocytosis and circulating blasts in peripheral blood. Bone marrow examination confirmed French-American-British (FAB) M4 AML. Scrotal ultrasound demonstrated heterogeneous masses, and computed tomography identified scalp chloromas without bone erosion. The patient received AML chemotherapy, resulting in resolution of extramedullary lesions and achievement of remission. This case underscores the importance of early hematologic evaluation in infants with bilateral testicular masses to prevent misdiagnosis. It illustrates the rare occurrence of concurrent testicular and scalp chloromas as the initial manifestation of infant AML.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"2024335"},"PeriodicalIF":0.7,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13659258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149185264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pregnancy-Associated Acquired Hemophilia A (PA-AHA) Treated Successfully With the Factor-Mimetic Bispecific Antibody Emicizumab: A Case Report and Literature Review. 拟因子双特异性抗体Emicizumab成功治疗妊娠相关获得性血友病A (PA-AHA): 1例报告及文献综述
IF 0.7
Case Reports in Hematology Pub Date : 2026-10-08 eCollection Date: 2026-01-01 DOI: 10.1155/crh/7527831
E Mandala, A Barmpouti, K Lafara, K Tsioni, T Achladas, K Kyrka, E Gavriilaki, C Lafaras, S Vakalopoulou
{"title":"Pregnancy-Associated Acquired Hemophilia A (PA-AHA) Treated Successfully With the Factor-Mimetic Bispecific Antibody Emicizumab: A Case Report and Literature Review.","authors":"E Mandala, A Barmpouti, K Lafara, K Tsioni, T Achladas, K Kyrka, E Gavriilaki, C Lafaras, S Vakalopoulou","doi":"10.1155/crh/7527831","DOIUrl":"https://doi.org/10.1155/crh/7527831","url":null,"abstract":"<p><p>Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by spontaneous bleeding in individuals with no previous personal or family history of bleeding, caused by the development of autoantibodies against coagulation Factor VIII (FVIII). These autoantibodies may be associated with drugs, autoimmune disorders, malignancies, and pregnancy. Pregnancy-associated AHA (PA-AHA) is a very rare condition, accounting for approximately 1%-5% of all AHA cases. Emicizumab, a bispecific FVIII-mimetic monoclonal antibody, was originally approved for Congenital Hemophilia A (with or without FVIII inhibitors) and has since gained widespread recognition and clinical utility in the management of AHA as well. We report a case of PA-AHA that was successfully managed with emicizumab. A 46-year-old woman was admitted with vaginal bleeding and extensive ecchymoses. The patient's obstetric history was notable for a twin gestation achieved through in vitro fertilization (IVF) using donor oocytes. The patient reported recurrent ecchymoses and menorrhagia beginning in the postpartum period. Laboratory examination revealed severe anemia with normal platelet counts and prothrombin time (PT), but a markedly prolonged activated partial thromboplastin time (aPTT) of 94.5 s. Immunological and virology testing, as well as cancer biomarkers, were negative. Initially, the patient received bypassing hemostatic therapy with recombinant activated Factor VII (rFVIIa), along with intensive immunosuppressive therapy (IST) consisting of corticosteroids, rituximab, and cyclophosphamide, in accordance with current international recommendations. However, no clinical response was observed. Treatment with emicizumab was subsequently initiated according to the proposed dosing schedule. Within 2 days, all bleeding manifestations resolved rapidly. Notably, FVIII activity, measured using a chromogenic assay, remained markedly reduced. After 566 days of follow-up, FVIII activity spontaneously normalized, allowing discontinuation of emicizumab. No further bleeding episodes were observed. Although emicizumab is increasingly incorporated into the management of AHA, clinical experience in PA-AHA remains limited. The present case adds to the existing literature by supporting the safety and efficacy of emicizumab in PA-AHA, highlighting its role as an effective hemostatic bridge to remission in complex clinical settings.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"7527831"},"PeriodicalIF":0.7,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD5-Positive Mature B-Cell Neoplasm With Large-Cell Morphology, Predominant Bone Marrow Involvement, and a Leukemic Peripheral Blood Presentation: A Case Report. cd5阳性成熟b细胞肿瘤伴大细胞形态,主要累及骨髓,外周血表现为白血病:1例报告。
IF 0.7
Case Reports in Hematology Pub Date : 2026-10-05 eCollection Date: 2026-01-01 DOI: 10.1155/crh/1476825
Masamitsu Takaba, Akari Yoda, Shinya Fujisawa
{"title":"CD5-Positive Mature B-Cell Neoplasm With Large-Cell Morphology, Predominant Bone Marrow Involvement, and a Leukemic Peripheral Blood Presentation: A Case Report.","authors":"Masamitsu Takaba, Akari Yoda, Shinya Fujisawa","doi":"10.1155/crh/1476825","DOIUrl":"https://doi.org/10.1155/crh/1476825","url":null,"abstract":"<p><p>A 65-year-old man presenting with pancytopenia and circulating large atypical cells was initially suspected of having acute leukemia. Flow cytometric analysis demonstrated a mature clonal B-cell phenotype, and the integrated findings supported a diagnosis of a CD5-positive mature B-cell neoplasm with large-cell morphology, predominant bone marrow involvement, and a leukemic peripheral blood presentation. Based on the available staging data, primary bone marrow DLBCL was suspected but could not be definitively confirmed. The neoplasm was characterized by CD5 expression, a <i>BCL6</i> rearrangement, and a complex karyotype including monosomy 17. The patient received six cycles of R-CHOP followed by two cycles of systemic high-dose methotrexate as individualized central nervous system prophylaxis. A complete response was confirmed after treatment, with no evidence of recurrence 6 months after treatment completion.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"1476825"},"PeriodicalIF":0.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13636136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149116437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional Antithrombin (AT) Deficiency Presenting as Multiterritorial Splanchnic Vein Thrombosis: A Case Report. 功能性抗凝血酶(AT)缺乏表现为多区域内脏静脉血栓:1例报告。
IF 0.7
Case Reports in Hematology Pub Date : 2026-10-05 eCollection Date: 2026-01-01 DOI: 10.1155/crh/9938304
Martha L Cuervo, Angela M Castañeda, Jaime A Pineda, Valentina Montiel, Jheremy E Reyes
{"title":"Functional Antithrombin (AT) Deficiency Presenting as Multiterritorial Splanchnic Vein Thrombosis: A Case Report.","authors":"Martha L Cuervo, Angela M Castañeda, Jaime A Pineda, Valentina Montiel, Jheremy E Reyes","doi":"10.1155/crh/9938304","DOIUrl":"https://doi.org/10.1155/crh/9938304","url":null,"abstract":"<p><p>Functional antithrombin (AT) deficiency is an inherited thrombophilic disorder that can present as venous thrombosis at atypical sites. We report the case of a 47-year-old man with a family history of venous thromboembolism who presented with thrombosis involving the splenoportal confluence and the superior mesenteric vein. Initial laboratory evaluation revealed normal AT activity levels and a negative standard thrombophilia panel. Due to the unusual thrombotic location and family history, extended genetic testing was performed, which identified a pathogenic heterozygous variant in <i>SERPINC1</i> NM_000488.3:c.749C > A (p.Thr250Asn), consistent with functional AT deficiency. After the resolution of gastrointestinal bleeding complications, long-term anticoagulation therapy was reintroduced. This case underscores the importance of considering hereditary thrombophilia in patients with thrombosis at unusual sites even when standard laboratory studies are unremarkable.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"9938304"},"PeriodicalIF":0.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13636659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149116453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书